PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma

Official Title
-----------------
A Randomized Phase II Study of Prednisone, Vinblastine, Doxorubicin, and Gemcitabine in Patients With Intermediate Stage Hodgkin's Lymphoma

Conditions
-----------------
Hodgkin Lymphoma

Intervention / Treatment
-----------------
* Drug: prednisone
* Drug: vinblastine
* Drug: doxorubicin
* Drug: gemcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically confirmed diagnosis of Hodgkin's lymphoma Stage Clinical Stage IA, IB, IIA with at least one of the risk factors a-d given below Clinical Stage IIB with one or both risk factors c-d given below risk factors: Large mediastinal mass (≥ 1/3 of the greatest thorax diameter as measured by chest x-ray) Extranodal involvement High erythrocyte sedimentation rate (≥ 50 mm/h in patients without B-symptoms, ≥ 30 mm/h in patients with B-symptoms) Three or more involved lymph node areas No prior therapy for Hodgkin's lymphoma (exception: pre-phase treatment with corticosteroids and vinca-alkaloids for a maximum of seven days may not preclude trial participation if clinically indicated and all staging examinations have been performed; all forms of prior radiotherapy preclude trial participation) Age: 18-60 years Signed informed consent with understanding of the study procedures and the investigational nature of the study Patient agrees that personal data and tissue samples are provided to the GHSG (protection of privacy as defined by law will be ensured) Life expectancy > 3 months according to investigator judgement. Exclusion Criteria: Incomplete diagnosis of stage of disease Prior or concurrent disease which prevents treatment according to protocol In particular the following contraindications: Chronic obstructive pulmonary disease with global insufficiency Symptomatic coronary heart disease Cardiomyopathy or cardiac insufficiency (NYHA value of EF < 50% or FS < 25%) Serious uncontrolled hypertension Uncontrollable infection Leucocyte concentration < 3.000/mm3 or thrombocyte concentration < 100.000/mm3 Creatinin clearance < 60 ml/min Bilirubin > 2 mg/dl or GPT > 100 U/l or GOT > 100 U/I (exception: elevated values of Hodgkin's disease liver involvement) HIV-Infection according to HIV test Chronic or acute Hepatitis HD as composite lymphoma Prior chemotherapy or radiation Malignant disease within the last 5 years (exceptions: basalioma, carcinoma in situ of the cervix uteri, completely resected melanoma TNMpT1) Pregnancy, lactation, positive pregnancy test Refusal to use effective contraception WHO performance index > 2 Long-term ingestion of corticosteroids (e.g. for chronic polyarthritis) or antineoplastic drugs (e.g. methotrexate) Patient's lack of accountability, inability to appreciate the nature, meaning and consequences of the trial and to formulate his/her own wishes correspondingly Non compliance: Refusal of blood products during treatment, epilepsy, drug dependency, change of residence abroad, prior cerebral injury or similar circumstances which appear to make protocol treatment or long-term follow-up impossible Antiepileptic treatment General intolerance of any protocol medication Any contraindication for study medication according to the summaries of product information Simultaneous participation in another clinical Institutionalization by law Relation of dependence with the sponsor's representative / trialist

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br> | Drug: prednisone<br> <br> Drug: vinblastine<br> <br> Drug: doxorubicin<br> <br> Drug: gemcitabine<br> <br> |
| Active Comparator: 2<br> | Drug: prednisone<br> <br> Drug: vinblastine<br> <br> Drug: doxorubicin<br> <br> Drug: gemcitabine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
intermediate stages